Cushing's disease
Drug research and approvals for cushing's disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 19 studies of cushing's disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, FDA has 4 approved and 0 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 19
- Trials authorized in Canada: 8
- FDA orphan approvals: 4
- EU medicines: 1
- Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal…NCT07920198 · Not reported · Azienda Ospedaliero-Universitaria di Modena · starts Jul 9, 2026
- Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph…NCT07463625 · Not reported · Hospices Civils de Lyon · starts Nov 23, 2023
- FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing DiseaseNCT07460232 · Early Phase 1 · Mayo Clinic · starts Apr 27, 2026
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol SecretionNCT07361874 · Phase 4 · University of Texas Southwestern Medical Center · starts Mar 5, 2026
- Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's SyndromeNCT07350707 · Phase 1 / Phase 2 · Peking Union Medical College Hospital · starts Dec 25, 2025
- Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's…NCT07335315 · Not reported · Mayo Clinic · starts Jun 19, 2024
- Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's SyndromeNCT07247162 · Phase 4 · RECORDATI GROUP · starts Aug 26, 2026
- Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CTNCT06962202 · Not reported · Post Graduate Institute of Medical Education and Research, Chandigarh · starts Aug 15, 2022
- Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's SyndromeNCT06801249 · Phase 4 · IRCCS Azienda Ospedaliero-Universitaria di Bologna · starts Feb 23, 2021
| Jun 17, 2026 | A double-blind, randomised, 30-week placebo-controlled phase IV study to assess the efficacy and safety of osilodrostat in patients with hypertension caused by…Osilodrostat (LCI699) | Recordati Rare Diseases | Pending |
| Sep 18, 2023 | Continuation of an open-label, multi-center study to assess long term safety in Canadian patients with endogenous Cushing's syndrome who have completed prior…Osilodrostat (LCI669) | Santé Québec- Centre Hospitalier De L’université De Montréal | Pending |
| Jun 4, 2019 | Glucocorticoid receptor antagonism in the treatment of Cushing syndrome (GRACE): a phase 3, double-blind, placebo-controlled, randomized-withdrawal study of…Relacorilant (CORT125134) | Corcept Therapeutics | Closed |
| Jul 19, 2018 | An open-label, multi-center, roll-over study to assess long term safety in patients with endogenous Cushing's sundrome who have completed a prior…Osilodrostat (LCI699) | Recordati Rare Diseases | Closed |
| May 2, 2017 | A phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of…Osilodrostat (LCI699) | Novartis Pharmaceuticals | Closed |
| Oct 8, 2014 | An open label study to assess the safety and efficacy of COR-003 (2s, 4r- ketoconazole) in the treatment of endogenous Cushing's syndromeKetoconazole (COR-003) | Cortendo AB | Closed |
| Jul 3, 2014 | A phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period…Osilodrostat (LCI699) | Novartis Pharmaceuticals | Closed |
| Apr 10, 2013 | An open label, multi-center pasireotide roll-over protocol for patients who have completed a previous novartis-sponsored pasireotide study and are judged by…Pasireotide (SOM230) | Recordati Rare Diseases | Closed |
| Apr 15, 2025 | IsturisaTreatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative | Recordati Rare Diseases Inc. | Approved |
| Mar 6, 2020 | IsturisaISTURISA is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery… | Recordati Rare Diseases, Inc | Approved |
| Jun 29, 2018 | SigniforSIGNIFOR® LAR is indicated for the treatment of patients with Cushing’s disease for whom pituitary surgery is not an option or has not been… | Novartis Pharmaceuticals Corporation | Approved |
| Dec 14, 2012 | SigniforTreatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative | Novartis Pharmaceuticals Corporation | Approved |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Apr 24, 2012 | SigniforPasireotide | Recordati Rare Diseases | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA